One of the significant challenges in targeting cross links in cancer therapy is the development of drug resistance. Cancer cells can sometimes enhance their DNA repair mechanisms or bypass the cross-linked damage, reducing the efficacy of treatments. Additionally, these therapies can cause side effects due to their lack of specificity, as they can also affect normal, healthy cells.
